SHC Vancomycin Dosing Guide

Similar documents
MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol

TDM of Aminoglycoside Antibiotics

Adult Institutional Pharmacokinetics Protocol

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

(Max 2 g) = to nearest 250 mg

AMINOGLYCOSIDES TDM D O N E B Y

PHA5128 Dose Optimization II Case Study 3 Spring 2013

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

VANCOMYCIN DOSING AND MONITORING GUIDELINES

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

Challenges in Therapeutic Drug Monitoring:

BSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

Approved by: SMG Origination Date: 06/14 Expiration Date: 06/17 Review Date: Revision Date: POLICY and PROCEDURE Archived Date: Page 1 of 14

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

IV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro

Evaluation of Vancomycin Continuous Infusion in Trauma Patients

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

PHA 5128 Spring 2009 First Exam (Version B)

D DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2

Cystatin C: A New Approach to Improve Medication Dosing

Clinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

AMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Intravenous Vancomycin Use Adult Inpatient/Ambulatory Clinical Practice Guideline

Vancomycin: Class: Antibiotic.

Career Corner: Pharmaceutical Calculations for Technicians. Ashlee Mattingly, PharmD, BCPS

PHA Case Studies V (Answers)

CAT. Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators. Apr. Glynis Frans Supervisor: Prof. Apr.

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Case Study 2 Answers Spring 2006

PHARMACOKINETICS SMALL GROUP II:

Counties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

TDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages

egfr 34 ml/min egfr 130 ml/min Am J Kidney Dis 2002;39(suppl 1):S17-S31

Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

Clinical Safety & Effectiveness Cohort # 10

Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults

Name: UFID: PHA Exam 2. Spring 2013

SBUH Aminoglycoside Dosing Protocol

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion

D DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1.

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Assessing Renal Function: What you Didn t Know You Didn t Know

PALO VERDE HEALTH CARE DISTRICT REGULAR BOARD OF DIRECTORS MEETING MINUTES July 27, 2016 City Council Chambers

Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis

Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Lessons from recent studies. João Gonçalves Pereira UCIP DALI

IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:

Moderator: Christina Cox, Pharm. D., BCPS, BCPPS Assistant Professor-Pediatrics, South Carolina College of Pharmacy, Columbia, South Carolina

Medication Dosing in CRRT

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

Clinical Study Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations

Superhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia

pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.

CRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017

Rationale for renal replacement therapy in ICU: indications, approaches and outcomes. Richard Beale

ICU Volume 11 - Issue 3 - Autumn Series

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS

Carboplatin Time to Drop the Curtain on the Dosing Debate

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

Selected Clinical Calculations Chapter 10. Heparin-Dosing calculations

Is the package insert correct? PK considerations

Gemcitabine + Cisplatin Regimen

PRINCIPLES OF PEDIATRIC PHARMACOTHERAPY. Marianne Krupicka, Pharm.D. Oregon Health and Science University/ Doernbecher Children s Hospital

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN

PHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq

PHAR 7632 Chapter 16

Renal Function and Associated Laboratory Tests

Renal function vs chemotherapy dosing

PHA Final Exam Fall 2006

THE AMINOGLYCOSIDE ANTIBIOTICS

PHA5128 Dose Optimization II Case Study I Spring 2013

Curve Your Enthusiasm: Using AUC:MIC pharmacokinetics to optimize vancomycin dosing

TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Doses Target Concentration Intervention

Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches

CLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel

Multiple IV Bolus Dose Administration

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

Can We Achieve Precision Solute Control with CRRT?

Learning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD

Optimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology

EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING

PHA 5128 Spring 2000 Final Exam

CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018

CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018

Can We Achieve Precision Solute Control with CRRT?

CRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT

(telavancin) Healthcare Professional s Guide. Version 2, 4 November 2014

GOOVIPPC. Protocol Code: Gynecology. Tumour Group: Paul Hoskins. Contact Physician: James Conklin. Contact Pharmacist:

Transcription:

SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring E: Dose Revisions F: Intermittent Hemodialysis Dosing Algorithms G: PK equations A. Initial Dosing Considerations 1. Review the following prior to initiation of therapy: a. Indication, relevant and pending microbial culture(s) b. Age, gender, height, weight, BMI c. Renal replacement therapy d. Special populations (obese, elderly, severely malnourished [BMI<16], amputees, pregnancy) e. Prior vancomycin dosing history (if applicable) f. Potential drug interactions g. Serum creatinine (SCr), urine output (if available), creatinine clearance (CrCl) i. Calculate CrCl using the Cockcroft-Gault equation (Figure 1) a) Elderly or severely malnourished: rounding SCr up is associated with underestimation of CrCl- clinical discretion advised [Smythe 1994, Young 2017, Barber 2016, Winter 2012] b) Use ideal body weight (IBW) for non-obese patients c) Use adjusted body weight (ABW) for obese patients [total body weight (TBW) >20% of IBW or BMI >30 kg/m 2 ] d) Use total body weight (TBW) if TBW < IBW Figure 1. Cockroft-Gault Equation CrCl ( ml min ) = (140 age) x IBW (x 0.85 for females) SCr x 72 IBW (male) = 50 kg + (2.3 x height in inches > 60 inches) IBW (female) = 45 kg + (2.3 x height inches > 60 inches) ABW (kg) = IBW + 0.4 (TBW IBW) h. Adverse Effects i. Red Man Syndrome is characterized by hypotension and/or a maculopapular rash appearing on the face, neck, trunk, and/or upper extremities. ii. If this occurs, pharmacist may slow the infusion rate (e.g. to 90-120 mins per 1 gm.) ± increase the dilution volume upon provider request ± recommend diphenhydramine 25-50mg premedication to the provider 1

B. Pharmacodynamic Targets: goal AUC and troughs Indication Target PD Index Most indications AUC-based protocol Trough-based protocol (dialysis, dose-by-level) Meningitis (empiric or definitive) MRSA infections with vanco MIC = 2 AUC-based protocol Trough-based protocol (dialysis, dose-by-level) AUC 400-700 Trough ~15 (10-20) AUC 600-800 Trough 15-20 In general, goal AUC/MIC 400 for S.aureus Monitor closely with trough > 15 or AUC > 700: increased risk of nephrotoxicity Vancomycin may be continued in clinically responding patients with MRSA w/vancomycin MIC = 2 C: Loading dose I. Purpose: Ensures (Area Under Curve)/(Minimum Inhibitor Concentration) of >400 mcg-h/ml is achieved on day 1 of therapy for bacterial killing in in vitro and clinical outcomes in vivo studies II. Targeted populations: Preferred in seriously ill (e.g. severe sepsis or septic shock requiring coverage for S. aureus) III. Standard load for patients with normal renal function: 25-30mg/kg TBW Patient Weight Standard Loading Dose ~25 mg/kg TBW Modified Loading Dose 15-20 mg/kg TBW Obese (BMI 30) CrCL < 30 or AKI, IHD, CRRT, unavailable Scr in emergent situations (e.g code sepsis or ED) 36 45 kg 1,000 mg x 1 750 mg x 1 46 55 kg 1,250 mg x 1 1,000 mg x 1 56 65 kg 1,500 mg x 1 1,250 mg x 1 66 75 kg 1,750 mg x1 1,500 mg x 1 76 120 kg 2,000 mg x 1 1,750 mg x1 > 120 kg 2,000 mg x 1 2,000 mg x 1 *Time maintenance dose start based on renal function: e.g. wait 24h to start maintenance regimen if CrCl = 30 Use total body weight (TBW); Round doses to nearest 250mg. Infuse each 1000mg over 60 minutes. Peripheral line: max 5mg/mL (including overfill) Central line only: Up to 1000 mg in 100 ml of compatible diluent 2

D: Initial Vancomycin Maintenance Dosing and Initial/Repeat Monitoring I. Round doses to nearest 250mg II. Maximum dose: 2gm per dose and 4.5g per 24h initially (including load) III. Repeat Vancomycin Levels A. After the target AUC or trough level is achieved at steady state, trough levels should be checked every 2 to 5 days until completion of therapy or discharge. Check peak/trough after any dose initiation/change. i. Levels should be checked sooner when clinically warranted (i.e.: change in clinical status or renal function, concern of accumulation/supratherapeutic levels, 25% change in trough/scr) B. If follow-up trough is within expected range, the AUC is likely within range as well C. If follow-up trough is outside expected range, obtain another level to recalculate AUC IV. Repeat SCr: q1-3 days if hemodynamically stable. Check daily if at high risk of nephrotoxicity. V. Can calculate an estimated total daily dose using PK equations (see Part G) or use the table below Creatinine Dose & Frequency Clearance Total body weight (TBW) (ml/min) TDD Range Timing of Peak/Trough Levels > 90 51-89 15 mg/kg Q8-12H BMI 30: 10 15 mg/kg TBW Q12H BMI 40: 7.5 12.5 mg/kg TBW Q12H 10 20 mg/kg Q12H BMI 30: 10 12.5 mg/kg TBW Q12H BMI 40: 7.5 10 mg/kg TBW Q12H 30 45 mg/kg/day Obese: 15 30 mg/kg TBW/day 20 40 mg/kg/day Obese: 15 25 mg/kg TBW/day 30-50 10-15 mg/kg Q12H to 20 mg/kg Q24H 20 30 mg/kg/day 10-29 10 15 mg/kg Q24H to 15 mg/kg Q48H 7.5 15 mg/kg/day <10 or AKI*, dose by level Hemodialysis CRRT 15 mg/kg x1, then dose by level N/A Initial: 15 20 mg/kg x 1 (max 2gm) Maintenance: see appendix E Initial: 15 20 mg/kg x 1 (max 2gm) Maintenance: 10 15 mg/kg Q24H N/A N/A Peak 1hr after 4 th / trough 30 min before 5 th dose, or Peak 1hr after 3 rd / trough 30 min before 4 th dose Q12H: Peak 1hr after 4 th / trough 30 min before 5 th dose, or Peak 1hr after 3 rd / trough 30 min before 4 th dose Q12H: as above Q24H: Peak 1hr after 3 rd / trough 30 min before 4 th dose Q24H Peak 1hr after 3 rd / trough 30 min before 4 th dose Q48H Peak 1hr after 2 nd dose; trough 30 min before 3 rd dose Trough within 24 hours of last dose, or with AM labs or every other day Single pre-dialysis level (preferred) Alternative: single level 4 hours after completion of dialysis session Trough 30 min before 3 rd or 4 th dose Check level 24h after initial dose. 10 15 mg/kg IV x1, then dose by level Consult ASP Peritoneal Dosing for intraperitoneal (IP) instillation Intraperitoneal dosing (off-protocol): N/A dialysis (NOT part of protocol) [Li, 2016] Level with AM labs on day 3 after any Intermittent (1 exchange/day): 15- dose administered (allow fluid 30mg/kg IP initially, then dose by level* redistribution before drawing random *supplemental doses may be needed for APD patients level) Note: For those with CrCL adjbw > 120mL/min, Q8H may be considered if t½ < 8hr** Loading and maintenance doses are based on 1-2L/hr dialysate flow and ultrafiltration rates, which is estimated to mimic a creatinine clearance of 30-50 ml/min *AKI (based on KDIGO, RIFLE, AKIN classifications): i. SCr change by 0.3 mg/dl within 48h or 50% from baseline or within last 7 days ii. CrCl change by >25-50% iii. Urine output < 0.5 ml/kg/hr over 6 hours (oliguria) **Calculating t½ in obesity Step Equation (adjusted for obese) Modified CLvanco 1 CL vanco = CrCladjBW x 0.06 (see right table) BMI 40 kg/m 2 max CL ~7 2 Vd = (0.5 0.7, see right table) x TBW Modified Vd 3 k = CLvanco/Vd BMI 30-40 kg/m 2 ~0.7 L/kg 4 t½ = 0.693/k BMI 40 kg/m 2 0.5 0.6 L/kg 3

E: Dose Revisions AUC calculator: This calculator is based on the Sawchuk-Zaske method and the equations used are summarized here. 11 Click here for link to AUC calculator on Microsoft Excel. AUC = t (Cmax Cmin) + 2 Cmax Cmin k t = infusion duration, k = ln C 1 C 2 Δt This AUC value applies to that calculated in a single dosing interval Δt must be multiplied by the dosing frequency when applicable to obtain the total AUC0-24 Cmax (true peak) and Cmin (true trough) are backcalculated from measured values using this equation: C 2 = C 1 e k t. (Details are in Part G) Linear proportion method: Once a calculated AUC or trough is obtained, changes to the total daily dose (TDD) have a corresponding proportional change in troughs and AUCs when maintaining the same dosing interval, assuming stable renal function and steady state conditions. AUC (calculated) AUC (desired) = Current TDD New TDD Cmin (observed) Cmin (desired) Current TDD = New TDD E.g.: 1250mg IV Q12H results in an AUC of 800. To target a AUC 600, reduce to 1g q12h (rounded up from 1875mg/day). Alternatively, converting the same TDD to a q8h regimen would result in a higher trough but would not impact the AUC. New TDD = 600 x 2500mg 800 = 1875mg Supratherapeutic levels and/or AKI: general approach A. Do not restart vancomycin until the random/trough level is estimated or confirmed to be at/near 10-20 mg/dl. Allow sufficient time for drug clearance before restarting next dose. B. Actions may include: pre-emptive dose adjustment, holding dose, checking level, discussion with provider, reassessing the need for vancomycin therapy. C. Consider SCr/renal trajectory when determining next dose and/or level 1. Ex) rapidly declining Scr may indicate improving renal function warranting earlier redosing vs. rapidly rising Scr indicating ongoing AKI- dose by level may be indicated 4

F: Intermittent Hemodialysis Dosing Algorithms For goal trough 10-20 mcg/ml: 5

For goal trough 15-20 mcg/ml: 6

G: PK Equations (same as those used in SHC Vancomycin Excel AUC Calculator) AUC-based dosing: initial dosing 1. Step 1: estimate Clvanco (L/hr)= ke x Vd a. Ducharme equation (most aggressive): ke = 0.0016 x CrCl i. Use in younger, previously healthy individuals w/out comorbidities b. Matzke Equation (least aggressive): ke = 0.00083 x CrCl +0.0044 i. For older patients and/or those with significant comorbidities 2. Step 2: estimate total daily dose = Clvanco x goal AUC0-24 AUC-based dosing: revision from 2 levels Step Description Equation 1 Verify that doses were given on time and drawn appropriately 2 Calculate the patient s observed k e from 2 levels k e = lnc 1 C2 t 2 t 1 where C 1 usually is the peak, C 2 is usually the trough 3 Calculate half-life, t 1/2 t 1/2 = 0.693 4 Calculate true peak, C max C max = C 1, Δt = time between end of infusion and time level drawn e k Δt 5 Calculate true trough, C min C min = C max e ke (tau t) where t = infusion time k 6 Calculate V d (steady state conditions) Dose (1 e Vd = k t ) t k e (C max [C min e k t ]) where t = infusion time 7 Calculate vancomycin clearance CL van = V d x k e 8 If C min is high, calculate the time needed to reach desired range ln C min C desired Time for C min to reach C desired = k e 9 Calculate AUC during infusion using linear trapezoidal rule AUC inf = t (C max + C min ) 2 10 Calculate AUC during elimination using logarithmic trapezoidal rule AUC elim = (C max C min ) k e 11 Calculate AUC 24 12 Estimate total daily dose need to achieve target AUC 24 Tip: new tau = 1 to 1.5x the half-life 13 Calculate predicted steady state C max for new dosing regimen 14 Calculate predicted steady state C min for new dosing regimen 15 Calculate predicted AUC based on new dosing regimen AUC 0 24 = (AUC inf + AUC elim ) 24 tau New TDD = Current TDD AUC 0 24 (calculated) AUC 0 24 (desired) New dose Css,max = CL t Same as step 5 Same as steps 9-11 1 e k tau 1 e k t Adapted from Detroit Medical Center: Vancomycin Dosing in Adults- Clinical Guidelines Jan 2015 Abbreviations t: infusion time; tau: dosing interval; Ke: elimination rate constant; Vd: volume of distribution; C 1: concentration at time t 1 (i.e. first of 2 levels drawn following dose); C 2: concentration at time t 2 (i.e. second of 2 levels drawn following dose) t 1: time at which C 1 is drawn t 2: time at which C 2 is drawn CL van: vancomycin clearance TDD: total daily dose AUC: area under the concentration-time curve AUC 24: 24 hour area under the concentration-time curve 7